# A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

> **NCT01821066** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PD-0332991 alone
- **DRUG:** Tamoxifen 60 mg
- **DRUG:** Tamoxifen 20 mg
- **DRUG:** PD-0332991 combination

## Key facts

- **NCT ID:** NCT01821066
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01821066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01821066, "A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01821066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*